EU Off-Patent Industry Sees ‘Limited Immediate Risk’ From COVID-19
But Coronavirus Could Have ‘Important Impact’ If Situation Continues
The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.
You may also be interested in...
European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.
India has published a list of APIs and formulations for which exports will be restricted, with immediate effect. The move comes against the backdrop of growing concerns over the off-patent industry’s supply chain given the ongoing pressures caused by the coronavirus outbreak.
The US Association for Accessible Medicines says it is actively working with industry stakeholders to mitigate coronavirus-related disruptions to the off-patent industry’s supply chain, with contingency planning a “top priority.”